Dr. Singh is currently a General Partner at Artiman Ventures in Silicon Valley and focuses on early-stage Technology and Life Sciences / Med-Tech investments. On behalf of Artiman, he serves on the Board of Directors of Aditazz, Inc., CardioDx Inc., CORE Diagnostics India Pvt. Ltd., and OncoStem Diagnostics Pvt Ltd.
Dr. Singh is also a Consulting Professor in the School of Medicine at Stanford University and is the Lead Director on Board of Directors of Max Healthcare, a healthcare delivery system comprised of an Academic Medical Center, Tertiary Care Centers, and clinics, based in New Delhi, India. He is the Chairman of the Board of Max Neeman, a CRO focused on Phase III and Phase IV Clinical trials in India and the Chair of the Board and Chair of the compensation Committee of SOFIE in Los Angeles.
Prior to joining Artiman, Dr. Singh was the President and CEO of BioImagene, a Digital Pathology company specializing in Cancer Diagnostics, based in Sunnyvale, CA. BioImagene was acquired by Roche in September 2010. Before BioImagene, Dr. Singh spent nearly twenty years at Siemens in various CEO roles. Between 1988 and 1995, he concurrently served on the faculty at Princeton University.
Dr. Singh has a Ph.D. in Computer Science from Columbia University, a master’s degree in Computer Engineering from Syracuse University and a bachelor’s degree in Electrical Engineering from Banaras Hindu University, India.
Dr. Singh is an active speaker in the Life Sciences, Information Technology, and Entrepreneurship communities. He has published two books and numerous refereed articles, and holds six patents.